News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,795 Results
Type
Article (44224)
Company Profile (131)
Press Release (473440)
Section
Business (144697)
Career Advice (2381)
Deals (27879)
Drug Delivery (108)
Drug Development (67756)
Employer Resources (148)
FDA (15545)
Job Trends (11924)
News (263152)
Policy (29552)
Tag
Academia (2282)
Alliances (35723)
Alzheimer's disease (1288)
Approvals (15453)
Artificial intelligence (122)
Bankruptcy (300)
Best Places to Work (9114)
Biotechnology (82)
Breast cancer (122)
Cancer (1060)
Cardiovascular disease (101)
Career advice (1988)
Cell therapy (235)
Clinical research (53732)
Collaboration (344)
Compensation (202)
COVID-19 (2546)
C-suite (91)
Data (1055)
Diabetes (152)
Diagnostics (5090)
Drug pricing (97)
Earnings (57151)
Employer resources (136)
Events (74771)
Executive appointments (273)
FDA (16085)
Funding (290)
Gene therapy (185)
GLP-1 (647)
Government (3795)
Healthcare (14702)
Infectious disease (2632)
Inflammatory bowel disease (101)
Interviews (444)
IPO (13798)
Job creations (3152)
Job search strategy (1660)
Layoffs (451)
Legal (6902)
Lung cancer (167)
Manufacturing (171)
Medical device (11056)
Medtech (11059)
Mergers & acquisitions (14156)
Metabolic disorders (441)
Neuroscience (1565)
NextGen Class of 2024 (4969)
Non-profit (3156)
Northern California (1369)
Obesity (260)
Opinion (188)
Patents (104)
People (41817)
Phase I (16016)
Phase II (23259)
Phase III (19153)
Pipeline (464)
Policy (87)
Postmarket research (2193)
Preclinical (6493)
Radiopharmaceuticals (202)
Rare diseases (226)
Real estate (4247)
Regulatory (20212)
Research institute (2049)
Resumes & cover letters (400)
Southern California (1167)
Startups (2735)
United States (11941)
Vaccines (621)
Weight loss (214)
Date
Today (123)
Last 7 days (556)
Last 30 days (3402)
Last 365 days (31792)
2024 (29370)
2023 (34981)
2022 (45057)
2021 (48500)
2020 (45514)
2019 (36210)
2018 (27396)
2017 (27804)
2016 (25803)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (667)
Arizona (138)
Asia (30505)
Australia (5341)
California (2989)
Canada (975)
China (192)
Colorado (131)
Connecticut (154)
Europe (74021)
Florida (428)
Georgia (103)
Illinois (267)
Indiana (154)
Maryland (542)
Massachusetts (2349)
Michigan (120)
Minnesota (219)
New Jersey (870)
New York (843)
North Carolina (649)
Northern California (1369)
Ohio (110)
Pennsylvania (747)
South America (1031)
Southern California (1167)
Texas (419)
Washington State (328)
517,795 Results for "pharmacosmos a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pharmacosmos Group to Acquire G1 Therapeutics
August 7, 2024
·
14 min read
Press Releases
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
September 5, 2024
·
6 min read
Policy
CSL Vifor Offers Marketing Campaign to Reverse Alleged Anti-Competitive Practices
Following an investigation regarding antitrust practices against Pharmacosmos’ Monofer, CSL Vifor has proposed a sweeping multi-channel communication campaign designed to reverse allegedly misleading messages about its rival.
April 22, 2024
·
2 min read
·
Tristan Manalac
Drug shortages
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded pharmacies are still making them. That’s unprecedented.
November 26, 2024
·
4 min read
·
Ben Hargreaves
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
Deals
Pharmacosmos Group Acquires Boston Based Clinical Stage AbFero Pharmaceuticals, Inc.
Pharmacosmos Group today announced the acquisition of AbFero Pharmaceuticals, Inc., a Boston based, privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload.
November 11, 2021
·
3 min read
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Huntington’s disease
Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data
After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.
November 20, 2024
·
2 min read
·
Tristan Manalac
1 of 51,780
Next